ArticleIndian journal of endocrinology and metabolism
Effect of Growth Hormone Therapy on Cardiometabolic Risk Factors, Hepatic Fat Content and Quality of Life in Patients with Sheehan's Syndrome.
Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Patients with Sheehan's syndrome (SS) commonly exhibit cardiovascular risk factors, including abdominal obesity, dyslipidaemia, hepatic steatosis and chronic inflammation. In addition, quality of life (QOL) is poor despite adequate replacement with glucocorticoids and thyroxine. This study evaluated the effects of growth hormone (GH) replacement on body mass index (BMI), lipid profile, body/hepatic fat and QOL in SS patients. Methods: This prospective study enrolled 14 SS patients with GH deficiency on stable hormonal therapy (excluding GH). Waist-hip ratio (WHR), BMI, lipids, liver steatosis and fibrosis, body fat (by dual energy X-ray absorptiometry) and QoL (using QOL in Adult GH Deficiency Assessment (QoL-AGHDA)) were assessed at baseline and after 24 weeks of GH replacement. Results: The mean age of the patients was 55.7 ± 6.9 years, with a mean disease duration of 19.4 ± 1.6 years (range, 8-27 years). After GH replacement, total cholesterol decreased from 213.35 ± 43.66 to 189.29 ± 23.49 mg/dl, LDL-cholesterol from 120.79 ± 38.73 to 89.36 ± 20.47 mg/dl and triglycerides from 288.79 ± 91 to 231.50 ± 47.15 mg/dl, while HDL-cholesterol increased from 41.29 ± 11.44 to 45.64 ± 4.39 mg/dl. Total body fat reduced from 39.97 ± 5.0% to 37.99 ± 4.5% ( Conclusion: GH replacement in SS patients improves lipid parameters, reduces body and hepatic fat and enhances QOL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.